Literature DB >> 10579470

The science of pharmacological variability: an essay.

W Kalow1, V Ozdemir, B K Tang, L Tothfalusi, L Endrenyi.   

Abstract

Mesh：

Year:  1999        PMID： 10579470     DOI： 10.1016/S0009-9236(99)70006-8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  12 in total

1.  Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

Authors:  Panga Jaipal Reddy; Rekha Jain; Young-Ki Paik; Robin Downey; Adam S Ptolemy; Vural Ozdemir; Sanjeeva Srivastava
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

2.  End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Authors:  Vural Ozdemir; Erik Fisher; Edward S Dove; Hilary Burton; Galen E B Wright; Mario Masellis; Louise Warnich
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-01-01

Review 3.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker?

Authors:  Semra Şardaş; Laszlo Endrenyi; Ulvi K Gürsoy; Mara Hutz; Biaoyang Lin; George P Patrinos; Lotte M G Steuten; Wei Wang; Louise Warnich; Vural Özdemir
Journal:  OMICS       Date:  2014-10-29

Review 5.  What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

Authors:  V Ozdemir; N H Shear; W Kalow
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

7.  Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

Authors:  Vural Ozdemir; Laszlo Endrenyi; Sükrü Aynacıoğlu; Nicola Luigi Bragazzi; Collet Dandara; Edward S Dove; Lynnette R Ferguson; Christy Jo Geraci; Ernst Hafen; Belgin Eroğlu Kesim; Eugene Kolker; Edmund J D Lee; Adrian Llerena; Muradiye Nacak; Kazutaka Shimoda; Toshiyuki Someya; Sanjeeva Srivastava; Brian Tomlinson; Effy Vayena; Louise Warnich; Umit Yaşar
Journal:  OMICS       Date:  2014-03-20

8.  Therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Smita Bhatia
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 9.  Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer       Date:  2014-10-29       Impact factor: 6.860

10.  Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.

Authors:  J Miao; Y Jin; R L Marunde; C J Gorski; S Kim; S Quinney; M Radovich; L Li; S D Hall
Journal:  Pharmacogenomics J       Date:  2009-06-09       Impact factor: 3.550
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.